The repair of osteochondral defects using baculovirus-mediated gene transfer with de-differentiated chondrocytes in bioreactor culture

Chen, Huang‐Chi; Chang, Yu‐Han; Chuang, Ching-Kuang; Lin, Chin-Yu; Sung, Li‐Yu; Wang, Yao‐Horng; Hu, Yu‐Chen

doi:10.1016/j.biomaterials.2008.10.017

Cited by 60 publications

(39 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…antibiotic resistance) and consequently irradiate them to prevent further in vivo growth and minimize tumour development [70,81]. Finally, the viral vector least employed is baculovirus, a virus that infects insect cells, but that is also able to transduce numerous mammalian cells, including chondrocytes and ADSCs for TGF-β [82] and BMPs [82,83] in vitro and in vivo. However, this virus is not able to replicate and integrate its DNAs into the chromosomes of transduced mammalian cells, determining a transient transgene expression (<7 days).…”

Section: Viral Vectormentioning

confidence: 99%

“…7). The cell vehicles, with and without scaffolds, are MSCs of different origin [14, 17, 26, 27, 40-42, 46, 54, 55, 59, 61, 71-75, 77, 82], chondrocytes [16,21,44,59,61,62,70,83] and, to a lesser extent, fibroblasts [18,56]. In fewer cases vectors are implanted into scaffolds without cells as vehicles: the plasmid vector is supported by a collagen I sponge or complexed with bPEI-HA via a porous oligo[poly(ethylene glycol) fumarate] hydrogel scaffold [22,24] and adenoviral vector by DCBM [51] (Table 1).…”

Section: Indirect Proceduresmentioning

confidence: 99%

“…The combination of gene therapy and scaffolds seems to greatly enhance both the efficiency and duration of transfected genes, leading to systems able to promote bone, cartilage, and osteochondral regeneration [22,23,26]. Scaffolds can be natural such as DBM, gelatine, alginate, fibrinogen and collagen based [16-18, 21, 27, 46, 52, 62, 71, 73, 84], or synthetic such as polyglycolic acid (PGA), polylactic acid (PLA) and poly(lactic-co-glycolide) (PLGA) [14,42,54,[82][83][84] (Table 1). Besides favouring cell engineering within the scaffold, their design can be used as guide for the correct integration and directional localization of cells in the defect.…”

Section: Use Of Scaffold In Gene Therapy Proceduresmentioning

confidence: 99%

See 2 more Smart Citations

Gene therapy for chondral and osteochondral regeneration: is the future now?

Bellavia

Veronesi

Carina

et al. 2017

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Gene therapy might represent a promising strategy for chondral and osteochondral defects repair by balancing the management of temporary joint mechanical incompetence with altered metabolic and inflammatory homeostasis. This review analysed preclinical and clinical studies on gene therapy for the repair of articular cartilage defects performed over the last 10 years, focussing on expression vectors (non-viral and viral), type of genes delivered and gene therapy procedures (direct or indirect). Plasmids (non-viral expression vectors) and adenovirus (viral vectors) were the most employed vectors in preclinical studies. Genes delivered encoded mainly for growth factors, followed by transcription factors, anti-inflammatory cytokines and, less frequently, by cell signalling proteins, matrix proteins and receptors. Direct injection of the expression vector was used less than indirect injection of cells, with or without scaffolds, transduced with genes of interest and then implanted into the lesion site. Clinical trials (phases I, II or III) on safety, biological activity, efficacy, toxicity or bio-distribution employed adenovirus viral vectors to deliver growth factors or anti-inflammatory cytokines, for the treatment of osteoarthritis or degenerative arthritis, and tumour necrosis factor receptor or interferon for the treatment of inflammatory arthritis

show abstract

Section: Viral Vectormentioning

confidence: 99%

Section: Indirect Proceduresmentioning

confidence: 99%

Section: Use Of Scaffold In Gene Therapy Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Gene therapy for chondral and osteochondral regeneration: is the future now?

Bellavia

Veronesi

Carina

et al. 2017

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

show abstract

“…В зависимости от медицинских показаний воз-можно использование хондроцитов, мультипотен-тных мезенхимальных стволовых клеток (ММСК) из различных источников (в основном из костного мозга (КМ) и жировой ткани (ЖТ), клеток-пред-шественников из надкостницы и надхрящницы или генетически-модифицированных клеток [22][23][24][25].…”

Section: технологии стимулирования регенерации поврежденной хрящевunclassified

Tissue Engineering and Regenerative Medicine Technologies in the Treatment of Articular Cartilage Defects

Басок

Севастьянов

2017

RJTAO

View full text Add to dashboard Cite

1 ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России, Москва, Российская Федерация 2 АНО «Институт медико-биологических исследований и технологий», Москва, Российская Федерация Важнейшими проблемами здравоохранения в индустриальном обществе являются повреждение и деге-нерация суставного хряща, что связано с ограниченными возможностями ткани к регенерации. В обзоре подробно описаны существующие и разрабатываемые технологии восстановления и замещения повреж-денных хрящевых тканей суставов. Дан анализ полученных результатов по двум основным направлени-ям: стимулирование регенерации поврежденной хрящевой ткани и выращивание элементов хрящевой ткани в биореакторах.Ключевые слова: суставной хрящ, клеточно-и тканеинженерные конструкции, регенеративная медицина, биореакторы. TISSUE ENGINEERING AND REGENERATIVE MEDICINE TECHNOLOGIES IN THE TREATMENT OF ARTICULAR CARTILAGE DEFECTS

show abstract

“…[198][199][200][201][202][203] Gene therapy approaches for cartilage regeneration have also been explored with transfection of cells with BMP-2, BMP-7, TGF-b1, IGF-1, among others, acting individually or in synergy. [204][205][206][207][208] Blocking angiogenic genes to prevent osteocalcification by using antiangiogenic factors or competitive inhibitors have also shown to promote cartilage regeneration. 209 Menendez et al 210 also assessed osteochondral repair after injection with adenoviral vectors of BMP-2 and BMP-6.…”

Section: From Single To Multiple Bioactive Factor Delivery For Skeletmentioning

confidence: 99%

Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery

Santo

Gomes²,

Mano³

et al. 2013

Tissue Engineering Part B: Reviews

105

View full text Add to dashboard Cite

The development of controlled release systems for the regeneration of bone, cartilage, and osteochondral interface is one of the hot topics in the field of tissue engineering and regenerative medicine. However, the majority of the developed systems consider only the release of a single growth factor, which is a limiting step for the success of the therapy. More recent studies have been focused on the design and tailoring of appropriate combinations of bioactive factors to match the desired goals regarding tissue regeneration. In fact, considering the complexity of extracellular matrix and the diversity of growth factors and cytokines involved in each biological response, it is expected that an appropriate combination of bioactive factors could lead to more successful outcomes in tissue regeneration. In this review, the evolution on the development of dual and multiple bioactive factor release systems for bone, cartilage, and osteochondral interface is overviewed, specifically the relevance of parameters such as dosage and spatiotemporal distribution of bioactive factors. A comprehensive collection of studies focused on the delivery of bioactive factors is also presented while highlighting the increasing impact of platelet-rich plasma as an autologous source of multiple growth factors.

show abstract

The repair of osteochondral defects using baculovirus-mediated gene transfer with de-differentiated chondrocytes in bioreactor culture

Cited by 60 publications

References 42 publications

Gene therapy for chondral and osteochondral regeneration: is the future now?

Gene therapy for chondral and osteochondral regeneration: is the future now?

Tissue Engineering and Regenerative Medicine Technologies in the Treatment of Articular Cartilage Defects

Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery

Contact Info

Product

Resources

About